Mar 5 |
Earnings Scheduled For March 5, 2024
|
Mar 4 |
Seres Therapeutics Q4 2023 Earnings Preview
|
Feb 28 |
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
|
Feb 27 |
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
|
Feb 26 |
Seres Therapeutics names Marella Thorell as CFO
|
Feb 26 |
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
|
Jan 30 |
Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
|
Jan 17 |
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jan 17 |
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
|
Jan 9 |
Seres Therapeutics reports VOWST prelim. Q4 sales of $10.4M; shares jump
|